Supplemental material
Journal of Market Access & Health Policy
Volume 5, 2017 - Issue 1
Open access
6,399
Views
20
CrossRef citations to date
0
Altmetric
Original Research Article
A comparative study of orphan drug prices in Europe
Katherine Eve YoungPricing, Reimbursement, Market Access, Creativ-Ceutical, Paris, FranceCorrespondence[email protected]
, Imen SoussiPricing, Reimbursement, Market Access, Creativ-Ceutical, Tunis, Tunisia
, Michiel HemelsMarket Access EMEA, Horizon Pharma, Utrecht, the Netherlands
& Mondher ToumiPublic Health Department, Aix-Marseille Université, Université de la Méditerranée, Marseille, France
http://orcid.org/0000-0001-7939-7204
Article: 1297886
|
Received 28 Nov 2016, Accepted 10 Feb 2017, Published online: 29 Mar 2017
Related Research Data
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Source:
Springer Science and Business Media LLC
Drugs for rare diseases: influence of orphan designation status on price.
Source:
Springer Science and Business Media LLC
G-BA benefit assessment of new orphan drugs in Germany: the first five years
Source:
Informa Healthcare
The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change.
Source:
Informa UK Limited
Congenital diaphragmatic hernia.
Source:
Springer Science and Business Media LLC
Orphan drugs policies: a suitable case for treatment
Source:
Springer Science and Business Media LLC
Pricing and reimbursement of orphan drugs: the need for more transparency
Source:
Springer Science and Business Media LLC
Access to orphan drugs in Europe: current and future issues
Source:
Informa UK Limited
Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.
Source:
Springer Science and Business Media LLC
Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
Source:
Springer Science and Business Media LLC
Shining a light in the black box of orphan drug pricing
Source:
Springer Nature
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Source:
Public Library of Science (PLoS)
What Is Wrong with Orphan Drug Policies
Source:
International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.